Exercise for Prevention and Treatment of Prostate Cancer: Cellular Mechanisms

  • R. James Barnard
  • William J. Aronson


Numerous epidemiological studies suggest that PA might reduce the risk for PCa but there are many inconsistencies in the data. Little is known about the value of exercise after diagnosis of PCa. Two studies report that resistance training during ADT increases muscular strength and reduces fatigue with no changes in body composition or in serum levels of testosterone or PSA. One study investigated the effects of aerobic exercise training on PCa patients during external beam RT and found an improvement in physical function with reduced fatigue. These were short-term studies with no PCa clinical outcomes. In a 1-year study, regular exercise combined with a low-fat, vegan diet and stress reduction reduced the need for aggressive treatment of the PCa. In obese men with no documented PCa, regular exercise, especially when combined with a low-fat diet, has been shown to reduce serum insulin and IGF-I, while increasing IGFBP-1 and SHBG. These serum changes result in reduced growth and increased apoptosis of androgen-dependent PCa cell lines in cultures. The effects on tumor cells appear to be associated with activation of the p53 gene and suggest that lifestyle modification may be important for both the prevention and treatment of PCa.


Resistance Training Exercise Intervention LNCaP Cell Exercise Group Cell Death Detection ELISA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by NCI Specialized Program of Research Excellence Grant P50 CA-921310, NCI Grant R01 CA-100938, The Veterans Administration, and a donation from the L.B. Research and Education Foundation.


  1. 1.
    Thune I, Furberg AS. (2001) Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc 33:S530–S550.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee IM. (2003) Physical activity and cancer prevention – data from epidemiologic studies. Med Sci Sports Exerc 35:1823–1827.CrossRefPubMedGoogle Scholar
  3. 3.
    Segal RJ, Reid RD, Courneya KS, et al. (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659.CrossRefPubMedGoogle Scholar
  4. 4.
    Galvao DA, Taaffe DR, Spry N, Newton RU. (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 10:340–346.CrossRefPubMedGoogle Scholar
  5. 5.
    Windsor PM, Nicol KF, Potter J. (2004) A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 101:550–557.CrossRefPubMedGoogle Scholar
  6. 6.
    Giovannucci E, Leitzmann M, Spiegelman D, et al. (1998) A prospective study of physical activity and prostate cancer in male health professionals. Cancer Res 58:5117–5122.PubMedGoogle Scholar
  7. 7.
    Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC. (2005) A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 165:1005–1010.CrossRefPubMedGoogle Scholar
  8. 8.
    Hu G, Tuomilehto J, Silventoinen K, Barengo NC, Peltonen M, Jousilahti P. (2005) The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47 212 middle-aged finnish men and women. Int J Obes (Lond) 29:894–902.CrossRefGoogle Scholar
  9. 9.
    Leitzmann MF, Park Y, Blair A, et al. (2007) Physical activity recommendations and decreased risk of mortality. Arch Intern Med 167:2453–2460.CrossRefPubMedGoogle Scholar
  10. 10.
    Orsini N, Mantzoros CS, Wolk A. (2008) Association of physical activity with cancer incidence, mortality, and survival: a population-based study of men. Br J Cancer 98:1864–1869.CrossRefPubMedGoogle Scholar
  11. 11.
    Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. (2002) Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (united states). Cancer Causes Control 13:929–935.CrossRefPubMedGoogle Scholar
  12. 12.
    Tymchuk CN, Barnard RJ, Heber D, Aronson WJ. (2001) Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. J Urol 166:1185–1189.CrossRefPubMedGoogle Scholar
  13. 13.
    Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ. (1998) Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 31:127–131.CrossRefPubMedGoogle Scholar
  14. 14.
    Tymchuk CN, Barnard RJ, Ngo TH, Aronson WJ. (2002) Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr Cancer 42:112–116.CrossRefPubMedGoogle Scholar
  15. 15.
    Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115–1118.PubMedGoogle Scholar
  16. 16.
    Wolk A, Mantzoros CS, Andersson SO, et al. (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90:911–915.CrossRefPubMedGoogle Scholar
  17. 17.
    Chan JM, Stampfer MJ, Giovannucci E, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566.CrossRefPubMedGoogle Scholar
  18. 18.
    Stattin P, Bylund A, Rinaldi S, et al. (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92:1910–1917.CrossRefPubMedGoogle Scholar
  19. 19.
    Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. (2003) Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144:2319–2324.CrossRefPubMedGoogle Scholar
  20. 20.
    Gurumurthy S, Vasudevan KM, Rangnekar VM. (2001) Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 20:225–243.CrossRefPubMedGoogle Scholar
  21. 21.
    Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. (2003) A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 56:201–206.CrossRefPubMedGoogle Scholar
  22. 22.
    Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. (2007) A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. Eur J Cancer Prev 16:415–421.CrossRefPubMedGoogle Scholar
  23. 23.
    Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. (2004) Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol 96:450–454.CrossRefPubMedGoogle Scholar
  24. 24.
    Bond VJ, Sridhar R, Kassa A, Blakely R, Austin R, Millis R. (2009) Aerobic fitness levels in African-American men, serum IGF-I, and growth of prostate cancer cells. Med Sci Sports Exerc 40:S289.Google Scholar
  25. 25.
    Heron-Milhavet L, LeRoith D. (2002) Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 277:15600–15606.CrossRefPubMedGoogle Scholar
  26. 26.
    Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ, LeRoith D. (2001) Insulin-like growth factor-i (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 276:18185–18192.CrossRefPubMedGoogle Scholar
  27. 27.
    Yu H, Rohan T. (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489.CrossRefPubMedGoogle Scholar
  28. 28.
    Lehman TA, Bennett WP, Metcalf RA, et al. (1991) P53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51:4090–4096.PubMedGoogle Scholar
  29. 29.
    Zhang Y, Fujita N, Tsuruo T. (1999) Caspase-mediated cleavage of p21waf1/cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 18:1131–1138.CrossRefPubMedGoogle Scholar
  30. 30.
    Tsujimoto Y. (2003) Cell death regulation by the bcl-2 protein family in the mitochondria. J Cell Physiol 195:158–167.CrossRefPubMedGoogle Scholar
  31. 31.
    Nelson WG, De Marzo AM, Isaacs WB. (2003) Prostate cancer. N Engl J Med 349:366–381.CrossRefPubMedGoogle Scholar
  32. 32.
    Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27:218–224.CrossRefPubMedGoogle Scholar
  33. 33.
    Ornish D, Weidner G, Fair WR, et al. (2005) Intensive lifestyle changes May affect the progression of prostate cancer. J Urol 174:1065–1069.CrossRefPubMedGoogle Scholar
  34. 34.
    Dewell A, Weidner G, Sumner MD, et al. (2007) Relationship of dietary protein and soy isoflavones to serum IGF-1 and IGF binding proteins in the prostate cancer lifestyle trial. Nutr Cancer 58:35–42.PubMedGoogle Scholar
  35. 35.
    Ornish D, Magbanua MJ, Weidner G, et al. (2008) Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA 105:8369–8374.CrossRefPubMedGoogle Scholar
  36. 36.
    Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59:3915–3918.PubMedGoogle Scholar
  37. 37.
    Goodyear LJ, Kahn BB. (1998) Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49:235–261.CrossRefPubMedGoogle Scholar
  38. 38.
    Samani AA, Yakar S, LeRoith D, Brodt P. (2007) The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28:20–47.CrossRefPubMedGoogle Scholar
  39. 39.
    Manes S, Llorente M, Lacalle RA, et al. (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935–6945.CrossRefPubMedGoogle Scholar
  40. 40.
    Roberts CK, Won D, Pruthi S, et al. (2006) Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 100:1657–1665.CrossRefPubMedGoogle Scholar
  41. 41.
    Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. (2001) Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem 276:33608–33615.CrossRefPubMedGoogle Scholar
  42. 42.
    Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030–1035.PubMedGoogle Scholar
  43. 43.
    Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609–2617.CrossRefPubMedGoogle Scholar
  44. 44.
    Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62:2942–2950.PubMedGoogle Scholar
  45. 45.
    Belfiore A. (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671–686.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Physiological ScienceUniversity of CaliforniaLos AngelesUSA
  2. 2.Department of UrologyDavid Geffin School of Medicine, University of CaliforniaLos AngelesUSA

Personalised recommendations